Home | Medical-Newswire.Com:
(Medical-NewsWire.com, October 25, 2019 ) Market Overview
Cancer biomarkers are a biological molecule secreted either by tumours or from tissues in response to cancer, which then later used to measure and evaluate the cancer growth processes in the body. Cancer biomarkers are used on or for the patients when undergone curative treatment for cancer; these can be further used to follow-up the disease condition at the early stage or for the possible recurrent disease. Various national governments are now focused to invest more in the processor to cure the disease at early stages or entirely to prevent the disease to be more worsened.
Majority of the healthcare bodies are into cancer research and its studies. Rising prevalence of cancer is in a way leading to innovation and development in the area of the cancer diagnosis with biomarkers. For instance, according to 2015, U.K. Department of Health & Social Care invested US 7.5 billion on cancer-related treatment and services, annually.
Cancer is one of the deadly diseases ever know. The high prevalence rate of cancer is expected to be a significant revenue booster for cancer biomarker market. For instance, according to cancer.gov, in 2018, an estimated 1,735,350 new cases of cancer will be diagnosed in the United States and 609,640 people will die from the disease. The listed descending order of most common cancer is breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. Breast cancer is the most common type of cancer and can occur both in men and women. However, it is mostly found among females, and the male occurrence of breast cancer is very rare. In 2018, an estimated 266,120 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S., along with 63,960 new cases of non-invasive (in situ) breast cancer. About 2,550 new cases of invasive breast cancer are expected to be diagnosed in men in 2018. A mans lifetime risk of breast cancer is about 1 in 1,000.
According to the World Cancer Research Fund (WCRF) International, 2015 data findings, 58% of the lung cancer cases were reported in emerging economies, in 2014. Hungary had the highest rate of lung cancer, followed by Serbia, and North Korea. Moreover, the highest incidence of lung cancer was registered in North America and Europe, for the same year. According to the National Cancer Institute, in 2014, around 66,771 people were suffering from liver, and intrahepatic bile duct cancer in the U.S. Liver and intrahepatic bile duct cancer represented 2.4% of all new cancer cases reported in the U.S. in 2014. Moreover, obesity, diabetes, alcoholic liver disease (cirrhosis), chronic hepatitis B, hepatitis C infections, tobacco, and smoking are the most common risk factors for liver cancer. According to the Centers for Disease Control and Prevention (CDC), February 2018 data findings, each year in the U.S., around 22,000 men and 9,000 women suffer from liver cancer, and about 16,000 men and 8,000 women die from liver cancer. Thus, the substantial increase in the incidence and mortality rate of liver cancer in the country is expected to boost the growth of the cancer biomarkers market, shortly. All such cancer is paving the way for new cancer diagnostic tests with the use of cancer biomarker, which might help in early detection of cancer, which can further impact the prevalence rate of cancer in middle and lower economic countries.
However, there are certain factors which are expected to hinder the cancer biomarker market are, high treatment cost and unfavorable reimbursement policies for cancer biomarkers. The cancer diagnosis is relatively expensive, which primarily includes medical and non-medical expenses for cancer diagnosis, treatment, and cancer care. For instance, according to the Cancer Action Network, in 2014, cancer patients in the U.S. paid around US 4 billion out-of-pocket for cancer treatment.
By biomarker type, genetic biomarker accounts for the largest share in the cancer biomarker market. The biomarker market is estimated to grow at a nominal of pace in the forecasted period growing at a CAGR of XX% in the predicted period 2018-2025.
Genetic Biomarker is defined as a DNA or RNA characteristic that is an indicator of normal biologic processes, pathogenic processes, and response to therapeutic or other intervention.
Genetic mutations are the primary causes for several cancer types and thus identifying these key mutations holds significant clinical importance in drug development, cancer diagnosis, and treatment.
The approval of novel gene-based assays and companion diagnostics will fuel the market for genetic biomarkers in the forecast period.
For instance, in January 2018, FDA has approved a PMA supplement extending the indications for the use of QIAGENs therascreen EGFR RGQ PCR Kit as a companion diagnostic to guide the use of Boehringer Ingelheims targeted therapy GILOTRIF for first-line treatment of NSCLC.
Segmentation by Cancer Indication
Segmentation by Biomarker Type
Segmentation by Profiling Technologies
Segmentation by Application
Drug Discovery And Development
Disease Screening and Diagnosis
Treatment Planning & Risk Assessment
North America accounts for the largest market share in 2017 with the market being dominated by the United States.
North America is dominating the cancer biomarkers market due to established R&D infrastructure and high acceptance of biomarker-based cancer testing, adequate reimbursement coverage in this region.
Also, the largest share of North America is due to the increasing government support for discovery and development of biomarkers, increasing demand for personalized medicine, high adoption of advanced omics technologies for biomarker discovery, and rising use of biomarkers in drug discovery and development by pharmaceutical companies in that region.
The US holds the largest market share in North America followed by Canada due to growing research and developments in cancer biomarkers with a rising number of cancer cases in this region.
On 5 December 2017, the European Cancer Patient Coalition (ECPC), in collaboration with the Member of the European Parliament Marlene Mizzi (S&D, Malta) organized an event on the topic of Cancer Biomarkers in the Era of Personalized Medicines.
The European Medicines Agency has endorsed a UK-US project to use an imaging biomarker to help select Parkinsons disease patients most likely to benefit from clinical trials.
India, China, Brazil, and Australia market are growing at a higher rate while United States, Italy, Germany, Japan, and Spain market are increasing at a slower pace but contribute to the most substantial market revenue in 2017.
Major players operating in the cancer biomarkers market include
Becton, Dickinson and Company,
Thermo Fisher Scientific Inc,
Merck & Co., Inc.,
BioMerieux S.A., Qiagen N.V.,
and Bard1 Life Sciences Limited among others.
Request Customization: https://www.datamintelligence.com/enquiry/cancer-biomarker-market
Download free sample: https://www.datamintelligence.com/download-sample/cancer-biomarker-market
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sales Manager at Data M Intelligence
Tel: +1 877 441 4866
+1 877 441 4866